Can a hospital network share an in-house test across multiple sites under Article 5(5)?

Generally no. The exemption is drafted for devices manufactured and used exclusively within a single health institution established in the Union, so distributing the assay across a multi-site network typically exceeds the scope of Article 5(5) and would require full IVDR compliance. This is a frequently overlooked boundary when institutions consolidate laboratory services.

What is the deadline pressure around Article 5(5) documentation right now?

Transitional provisions extended certain Article 5(5) documentation deadlines to 2028 and 2030 depending on device risk class, but the underlying conditions, including the QMS and the justification that no equivalent CE-marked device meets the patient need, apply from now. Institutions should not treat the extended documentation deadline as delaying the operational requirements.

Is an in-house device the same as a laboratory-developed test?

In-house IVDs under Article 5(5) are the EU regulatory analogue of what is commonly called a laboratory-developed test (LDT) in other jurisdictions, but the EU term is defined narrowly by the health-institution manufacturing and use conditions in the IVDR text. Referring to a device informally as an LDT does not itself establish eligibility for the Article 5(5) exemption.

All terms

RegulatoryRegulated Pathways Global Markets

In-House IVDs (Article 5(5))

Devices manufactured and used within a single EU health institution under conditions in IVDR Article 5(5).

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed July 25, 2026

Definition

Article 5(5) exempts devices manufactured and used exclusively within health institutions established in the Union from most IVDR requirements, provided conditions are met: an appropriate quality management system, justification that patient needs cannot be met by an equivalent CE-marked device, documentation on manufacturing and performance, and public declaration and reporting to the competent authority.

What the regulation says

Regulation (EU) 2017/746 (IVDR), adopted on 5 April 2017 and generally applicable from 26 May 2022, establishes the health institution exemption in Article 5(5). Devices manufactured and used only within Union health institutions remain subject to the relevant general safety and performance requirements in Annex I, but can be exempt from other IVDR requirements if the applicable conditions are satisfied. Devices must not be transferred to another legal entity, and the exemption does not cover industrial-scale manufacture. The framework includes an appropriate quality management system and laboratory compliance with EN ISO 15189 or applicable national provisions, including accreditation requirements. Article 5(5) also provides for documented justification that an equivalent marketed device cannot meet the target patient group's needs at an appropriate performance level. Institutions must publish a declaration identifying themselves and the devices and addressing Annex I compliance, provide information to competent authorities on request, and review clinical-use experience to implement corrective action. Detailed manufacturing, design and performance documentation is expressly required for class D devices; Member States may extend this requirement to other classes. MDCG 2023-1, published on 19 January 2023, provides non-binding interpretive guidance for this MedTech exemption, rather than replacing the regulation.

What this means in practice

In-house diagnostics (also known as laboratory-developed tests or LDTs in EU practice) are a major route for niche and rapidly evolving assays. Transition provisions extended key Article 5(5) documentation deadlines to 2028 and 2030 for high-risk classes, but the basic conditions apply now.

Examples

A university hospital's genetic laboratory develops a highly specialized PCR assay to detect a rare genetic mutation for which no CE-marked diagnostic kit is commercially available, serving a small patient cohort with a unique clinical need.
A national public health laboratory creates an in-house immunoassay to rapidly identify a novel pathogen during an emerging infectious disease outbreak, providing critical diagnostic capabilities before commercial kits are developed.
A specialized cancer treatment center devises a laboratory-developed test to monitor specific biomarkers for a rare oncology drug response, tailoring patient management based on real-time data where no equivalent commercial test exists.

Common pitfalls

•Assuming the exemption covers cross-institution networks. It applies to a single health institution.
•Overlooking the requirement to justify that no equivalent CE-marked device meets the need.

Frequently asked questions

No. Article 5(5) exempts in-house devices from most IVDR requirements but not all of them: the health institution must operate an appropriate quality management system, justify that patient needs cannot be met by an equivalent CE-marked device, document manufacturing and performance information, and publicly declare and report the device to the competent authority. It is a conditional exemption, not a blanket carve-out.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

EU In Vitro Diagnostic Regulation(IVDR)

Regulation (EU) 2017/746 governing in vitro diagnostic medical devices in the EU.

Market Segments

Laboratory-Developed Test(LDT)

IVD designed, manufactured, and used within a single CLIA laboratory.

More in Regulatory

· Same category

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Regulatory

510(k) Summary vs 510(k) Statement

Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.

Regulatory

513(g) Request for Information(513(g))

Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.

Regulatory

Abbreviated 510(k)

510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (2)

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2

Link health: 2 verified 1 unchecked· last checked 2026-06-20

EUR-Lex·1MDCG·1IMDRF·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Regulatory0 / 101

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Regulatory
Sources: 3
Updated: 7/25/2026

Compare with another term

Learn in 60 seconds

Devices manufactured and used within a single EU health institution under conditions in IVDR Article 5(5).

·In-house diagnostics (also known as laboratory-developed tests or LDTs in EU practice) are a major route for niche and rapidly evolving assays.
·Transition provisions extended key Article 5(5) documentation deadlines to 2028 and 2030 for high-risk classes, but the basic conditions apply now.

Remember this

Watch out: Assuming the exemption covers cross-institution networks. It applies to a single health institution.

Related terms

You may also need

Auto-suggested from Regulatory and shared keywords.

All Regulatory terms

From the Blue Goat network

Related resources and services on this topic.